Defining Treatment Goals and Addressing Unmet Needs in Psoriasis

In this episode, ‘Defining Treatment Goals and Addressing Unmet Needs in Psoriasis,’ the expert dermatologists explore the evolution of patient expectations and the clinical necessity of aggressive disease management. Dr. Mark Lebwohl explains that his primary objective aligns with the National Psoriasis Foundation treat to target guidelines, which aim for less than 1% body surface area involvement. He argues that this goal is vital because psoriasis is a systemic inflammatory condition rather than a localized skin issue. Dr. Lebwohl notes that severe psoriasis can triple the risk of heart attacks in young patients, making effective treatment essential for cardiovascular and joint health.

Dr. Tina Bhutani-Jacques adds that while patients may be hesitant to commit to lifelong therapy, the risks of under treatment often outweigh the potential side effects of modern medications. She points out that achieving total clearance is now a realistic possibility for many patients, though significant unmet needs remain. The experts identify specific challenges such as nail psoriasis and palmoplantar psoriasis, where current therapies still struggle to produce consistent results. They also discuss the need for better management of psoriatic arthritis and the pursuit of PASI 100 scores across more of the patient population. Reflecting on the history of the field, the doctors contrast the dangerous and less effective treatments of the past with the current landscape, concluding that striving for tighter disease control is a necessary standard of care to prevent long term comorbidities.

The next episode in this series, ‘The Role of TYK2 Inhibitors in Modern Psoriasis Care,’ features the panelists discussing the mechanism of action of TYK2 inhibitors and how they provide a highly selective oral alternative to injectable biologics. Dr. Bhutani-Jacques and Dr. Lebwohl explain how these agents block specific cytokine signaling while maintaining a favorable safety profile compared to traditional JAK inhibitors.